 |
MentiNova
Last updated: May 01, 2024
M. Maral Mouradian, Founder, President and Chair of the Board
Country: USA | Funding: $500K (+)
Website: http://mentinova.com/
MentiNova’s primary strategy is to use L-DOPA, the drug that is currently clinically approved for another indication and repurpose it for the treatment of L-Dopa Induced Dyskinesia in patients with Parkinson’s disease.
Website: http://mentinova.com/
MentiNova’s primary strategy is to use L-DOPA, the drug that is currently clinically approved for another indication and repurpose it for the treatment of L-Dopa Induced Dyskinesia in patients with Parkinson’s disease.
